24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Study Sheds Light on Why COVID-19 Hits Elderly HardestDuring Stress of Pandemic, Know Suicide's Warning SignsEarly Results Show Moderna's COVID Vaccine Safe, Effective in Older PeoplePandemic Has More Americans Turning to BoozeStudy Confirms Minorities Face Higher Odds of COVID-19: StudyLockdown Could Worsen Hearing Woes for U.S. SeniorsGlobal Death Toll From COVID-19 Passes One MillionWarming World Could Alter West Nile Transmission in U.S.Most Newborns of COVID-19-Infected Moms Fare WellCOVID Antibodies Found in Less Than 10% of AmericansCOVID-19 Patients Rarely Survive Cardiac Arrest: StudyLow Vitamin D Levels Tied to Higher Odds for Severe COVIDKids Much Less Prone to Coronavirus Infection Than Adults: Study'Silent' COVID-19 Produces as Much Virus as in Patients With Symptoms: StudyImmune System Clues to Why COVID Is Easier on KidsU.S. Coronavirus Cases Top 7 MillionAccuracy of COVID-19 Antibody Tests Varies Widely, Study FindsAmerica's COVID Pandemic Is Now Skewing YoungerEven If Hips, Legs Slim Down, Belly Fat Remains a Health DangerAfter COVID-19 Exposure, When Can Young Athletes Resume Play?Kids Who Need Steroids Face Risk of Diabetes, Other Ills9 in 10 Americans Not Yet Immune to COVID, CDC Director SaysCommon Heart Defect Limits Exercise Ability: StudyBlood Test Could Spot Those at Highest Risk for Severe COVID-19Singing Without a Face Mask Can Spread COVID-19Could Zinc Help Fight COVID-19?U.S. COVID Death Toll Hits 200,000 as Cases Climb in 22 States4 Out of 5 People With COVID-19 Will Develop Symptoms: StudyMany Health Care Workers Who Have Coronavirus Don't Have Symptoms: StudyAHA News: Cluster of Risky Conditions That Can Lead To Heart Disease Is Rising in Hispanic AdultsMinorities Hit Hardest When COVID Strikes Nursing HomesAvoid the 'Twindemic:' Get Your Flu Shot NowCertain Cancer Treatments May Heighten Danger From COVID-19Homemade Masks Do a Great Job Blocking COVID-19Having Flu and COVID Doubles Death Risk in Hospitalized PatientsGuard Yourself Against the Health Dangers of Wildfire SmokeLife Expectancy Could Decline Worldwide Due to COVID-19Potential COVID-19 Drug Could Increase Heart Risk: StudyU.S. COVID Death Toll Nears 200,000, While Cases Start to Climb AgainCDC Reverses COVID Test Guideline After ControversyAs Schools Reopen, Many Students, Staff Live With High-Risk Family MemberCOVID-19 Poses Added Risk for People With Addiction Disorders: StudyGetting a Hip Replacement? Choice of Hospital Can Be CrucialAlmost 90,000 Young American Adults Will Get Cancer This Year: ReportAnother Rapid COVID-19 Test Shows PromiseDetails Emerge on Unexplained Illness in AstraZeneca COVID Vaccine TrialRising Obesity Levels Put Americans at Risk During Pandemic: CDCMore Pets May Be Getting COVID-19 Than RealizedWildfire Smoke Poses Special Threat to People With AsthmaCOVID-19 Prevention Might Translate Into Record Low Flu Rates: CDC
Questions and AnswersLinks
Related Topics

Diabetes

Pfizer's COVID Vaccine Shows 'Robust' Results in Early Trial

HealthDay News
by By E.J. Mundell
HealthDay Reporter
Updated: Aug 12th 2020

new article illustration

WEDNESDAY, Aug. 12, 2020 (HealthDay News) -- A vaccine based on cutting-edge RNA gene technology showed promising potency against the new coronavirus in an early trial, scientists report.

The vaccine candidate -- for now just called BNT162b1 -- "elicited a robust immune response in participants, which increased with dose level and with a second dose," according to a news release from the journal Nature, which published the trial data on Aug. 12.

The early phase 1/2 trial was led by Dr. Judith Absalon, of drug giant Pfizer Inc. According to her team, BNT162b1 is based on a bit of genetic code known as messenger RNA, which helps kick-start the body's immune response when it encounters the new coronavirus.

Vaccine development strategies focused on RNA are "generally considered safe and have facilitated the rapid development of vaccines against SARS-CoV-2," the journal noted.

The new trial involved 45 healthy adults between the ages of 18 and 55. Half were randomly selected to get the vaccine at a low, medium or high dose, while the other half got a "dummy" placebo shot.

The result: "The vaccine elicited a robust immune response in participants," and the higher the dose, the stronger the response, the authors reported. Getting a second "booster" shot also upped the immune system response.

In fact, in participants who got the vaccine, "levels of [coronavirus-] neutralizing antibodies were 1.9 to 4.6 times higher than those in patients recovering from SARS-CoV-2," according to the release. Still, Absalon's group stressed that phase 3 trials -- where the vaccine is tested in a much larger population -- are needed to confirm the safety, strength and duration of any protective effect.

According to the journal, the shot was "generally well-tolerated," although some recipients did have some transitory side effects such as soreness at the injection site, fatigue, headache, fever and sleep woes. Those tended to clear up within a week of vaccination, the researchers said.

Dr. Amesh Adalja is an expert in infectious diseases and a senior scholar at the Johns Hopkins Center for Health Security in Baltimore. Reading over the new report, he said, "The study provides more evidence of mRNA candidate COVID vaccines do induce neutralizing antibodies after two doses."

Adalja noted that there are "multiple" COVID-19 vaccine candidates that employ RNA technology, and this suggests they can spark a potent immune response in people.

"What remains to be seen is what these antibodies translate to when a vaccinated individual is faced with the wild virus," Adalja said. "Until we see phase 3 clinical data, it is still an extrapolation to understand how effective these vaccines will be in the real world."

More information

The U.S. Centers for Disease Control and Prevention has more on the new coronavirus.